Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Blood (2024) 144 (Supplement 1): 4947.

https://doi.org/10.1182/blood-2024-202933

Published: 2024

Journal Articles

Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 3565.

https://doi.org/10.1182/blood-2024-201944

Published: 2024

Journal Articles

Bendamustine in Combination with Gemcitabine and Vinorelbine As Salvage Regimen for Relapsed or Refractory Peripheral T-Cell Lymphomas: A Retrospective Single Center Experience

Filippo Bagnoli, Jacopo Calabrese De Feo, Francesca Livia Letizia Ricci, Jacopo Mariotti, Barbara Sarina, Monica Balzarotti, Daniela Taurino, Daniele Mannina, Chiara De Philippis, Daoud Rahal, Arturo Bonometti, Massimo Magagnoli, Rita Mazza, Marcello Rodari, Laura Giordano, Stefania Bramanti, Carmelo Carlo-Stella, Armando Santoro

Blood (2024) 144 (Supplement 1): 1681.

https://doi.org/10.1182/blood-2024-203287

Published: 2024

Journal Articles

Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC

Blood (2023) 142 (Supplement 1): 4899.

https://doi.org/10.1182/blood-2023-181815

Published: 2023

Journal Articles

Impact of Daratumumab on Hematopoietic Stem Cell Mobilization with G-CSF and on-Demand Plerixafor in Newly-Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 6633.

https://doi.org/10.1182/blood-2023-180082

Published: 2023

Journal Articles

Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide

Giuseppe Lia, PhD, Clara Di Vito, PhD, Marta Tapparo, PhD, Stefania Bruno, Elisa Zaghi, Michela Calvi, Lucia Brunello, Jacopo Mariotti, MD, Lorenzo Comba, Luisa Giaccone, Martina Fascì, Mario Boccadoro, Andrea Evangelista, MSc, Luca Castagna, MD, Giovanni Camussi, Domenico Mavilio, Benedetto Bruno, MD

Blood (2019) 134 (Supplement_1): 598.

https://doi.org/10.1182/blood-2019-126521

Published: 2019

Journal Articles

CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy

Jacopo Mariotti, Stefania Bramanti, Raynier Devillier, MD PhD, Barbara Sarina, Sabine Furst, MD, Angela Granata, MD, Valerio Maisano, MD, Thomas Pagliardini, MD, Chiara De Philippis, MD, Catherine Faucher, MD, Samia Harbi, MD, Christian Chabannon, MD PhD, Carmelo Carlo-Stella, MD, Reda Bouabdallah, Armando Santoro, Didier Blaise, MD PhD, Luca Castagna

Blood (2019) 134 (Supplement_1): 4484.

https://doi.org/10.1182/blood-2019-125101

Published: 2019

Journal Articles

Haploidentical Allogeneic Hematopoietic Cell Transplantation for Mantle Cell Lymphoma Using Post-Transplantation Cyclophosphamide Graft-Versus-Host Disease Prophylaxis

Chiara De Philippis, MD, Jacopo Mariotti, MD, Reda Bouabdallah, MD, Raynier Devillier, Stefania Bramanti, MD, Samia Harbi, MD, Sabine Furst, MD, Faezeh Legrand, MD, Barbara Sarina, MD, Carmelo Carlo-Stella, MD, Armando Santoro, MD, Didier Blaise, Luca Castagna

Blood (2018) 132 (Supplement 1): 5748.

https://doi.org/10.1182/blood-2018-99-117005

Published: 2018

Journal Articles

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Armando Santoro, MD, Luca Castagna, MD, Massimo Magagnoli, MD, Stefania Bramanti, MD, Jacopo Mariotti, MD, Rita Mazza, MD, Lucia Morello, MD, Francesca Ricci, MD, Barbara Sarina, MD, Chiara De Philippis, MD, Simona Sica, MD, Marcello Rodari, MD, Martina Sollini, MD, Margarita Kirienko, MD, Laura Giordano, Arturo Chiti, MD, Paolo Corradini, MD, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2018-99-118127

Published: 2018

Journal Articles

Severe Cytokine Release Syndrome Is a Fatal Complication after PBSC, but Not after BM Haploidentical Transplantation with Post-Transplant Cyclophosphamide

Jacopo Mariotti, Daniela Taurino, MD, Stefania Bramanti, MD, Barbara Sarina, MD, Lucio Morabito, Carmelo Carlo-Stella, MD, Armando Santoro, MD, Luca Castagna, MD

Blood (2017) 130 (Supplement 1): 665.

https://doi.org/10.1182/blood.V130.Suppl_1.665.665

Published: 2017

Journal Articles

Gvhd after PBSC-Haploidentical Stem Cell Transplantation (Haplo-SCT) with Post Transplantation-Cyclophosphamide (PT-Cy)

Angela Granata, MD, Raynier Devillier, Stefania Bramanti, MD, Sabine Furst, MD, Faezeh Legrand, MD, Samia Harbi, MD, Catherine Faucher, MD, Christian Chabannon, MD PhD, Claude Lemarie, Pharm.D., Boris Calmels, Pharm.D., Jacopo Mariotti, Valerio Maisano, MD, Pierre Jean Weiller, MDPhD, Luca Castagna, MD, Didier Blaise

Blood (2017) 130 (Supplement 1): 1984.

https://doi.org/10.1182/blood.V130.Suppl_1.1984.1984

Published: 2017

Journal Articles

The Minnesota Refined Acute GVHD Score Predicts Response to Initial Therapy, Survival and Non-Relapse Mortality after Haploidentical Transplantation with Post-Transplant Cyclophosphamide

Jacopo Mariotti, Angela Granata, MD, Raynier Devillier, Stefania Bramanti, MD, Barbara Sarina, MD, Sabine Furst, MD, Catherine Faucher, MD, Samia Harbi, MD, Lucio Morabito, Christian Chabannon, MD PhD, Carmelo Carlo-Stella, MD, Reda Bouabdallah, MD, Armando Santoro, MD, Didier Blaise, Luca Castagna, MD

Blood (2017) 130 (Supplement 1): 4485.

https://doi.org/10.1182/blood.V130.Suppl_1.4485.4485

Published: 2017

Journal Articles

CD3 Lymphocyte Graft Content and Not Hematopoietic Stem Cell Source Is Associated to Higher Chronic GVHD after Haploidentical Transplantation with Post-Transplant Cyclophosphamide

Alberto Mussetti, MD, Chiara De Philippis, MD, Cristiana Carniti, Mariana Bastos Oreiro, MD, Jorge Gayoso, MD, Nicoletta Cieri, MD PhD, Fabio Ciceri, MD, Raffaella Greco, MD, Francesca Patriarca, MD, Jacopo Mariotti, Luca Castagna, MD, Paolo Corradini, MD

Blood (2017) 130 (Supplement 1): 4587.

https://doi.org/10.1182/blood.V130.Suppl_1.4587.4587

Published: 2017

Journal Articles

Reduced Relapse and Improved Survival in Chemosensitive Hodgkin Lymphoma Patients Undergoing Haploidentical Related Donor Compared to HLA-Identical Donor Transplantation

Blood (2017) 130 (Supplement 1): 3309.

https://doi.org/10.1182/blood.V130.Suppl_1.3309.3309

Published: 2017

Journal Articles

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

Jacopo Mariotti, MD, Anna Guidetti, MD, Michele Magni, MD, Paola Matteucci, MD, Liliana Devizzi, MD, Andrés J.M. Ferreri, Paolo Corradini, MD, Anna Dodero, MD, Amalia De Renzo, Alessandro Massimo Gianni, MD, Massimo Di Nicola, MD

Blood (2014) 124 (21): 1734.

https://doi.org/10.1182/blood.V124.21.1734.1734

Published: 2014

Journal Articles

Pharmacologic Inhibition of JAK1/JAK2 Signaling Protects from Acute GvHD While Preserving Gvt in Mice

Cristiana Carniti, Silvia Gimondi, Antonio Vendramin, Camilla Recordati, DVM, PhD Dipl. ECVP, Davide Confalonieri, Anisa Bermema, Paolo Corradini, MD, Jacopo Mariotti, MD

Blood (2014) 124 (21): 1107.

https://doi.org/10.1182/blood.V124.21.1107.1107

Published: 2014

Journal Articles

In Vivo Jak1/Jak2 Inhibition Protects From Acute GvHD While Maintaining Robust Anti-Tumor Activity

Cristiana Carniti, Silvia Gimondi, Antonio Vendramin, Davide Confalonieri, Camilla Recordati, DVM, PhD, Dipl. ECVP, Anisa Bermema, Jacopo Mariotti, Paolo Corradini

Blood (2013) 122 (21): 4481.

https://doi.org/10.1182/blood.V122.21.4481.4481

Published: 2013

Journal Articles

Phase 2 clinical trial of rapamycin-resistant donor CD4 + Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation

Blood (2013) 121 (15): 2864–2874.

https://doi.org/10.1182/blood-2012-08-446872

Published: 2013

Includes: Supplemental data

Journal Articles

Inhibition of Jak1/Jak2 Is More Effective Than Inhibition of Jak3 in Protecting Mice From Acute Graft-Versus-Host Disease (aGvHD) by Significantly Decreasing Alloreactive CD4+ T-Cells.

Cristiana Carniti, PhD, Silvia Gimondi, Raffaella Vaccaroli, Antonio Vendramin, PhD, Anisa Bermema, Enrico Radaelli, DVM, PhD, Jacopo Mariotti, MD, Paolo Corradini, MD

Blood (2012) 120 (21): 2997.

https://doi.org/10.1182/blood.V120.21.2997.2997

Published: 2012

Journal Articles

G-CSF Stem Cell Mobilization Is Protective Against Acute Graft-Versus-Host Disease (aGvHD) by Increasing Myeloid-Derived Suppressor Cell (MDSC) Frequencies

Cristiana Carniti, PhD, Antonio Vendramin, PhD, Silvia Gimondi, Anisa Bermema, Fabiana Riva, Jacopo Mariotti, MD, Paolo Corradini, MD

Blood (2012) 120 (21): 1898.

https://doi.org/10.1182/blood.V120.21.1898.1898

Published: 2012

NARROW

Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)

Bendamustine in Combination with Gemcitabine and Vinorelbine As Salvage Regimen for Relapsed or Refractory Peripheral T-Cell Lymphomas: A Retrospective Single Center Experience

Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC

Impact of Daratumumab on Hematopoietic Stem Cell Mobilization with G-CSF and on-Demand Plerixafor in Newly-Diagnosed Multiple Myeloma Patients

Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide

CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy

Haploidentical Allogeneic Hematopoietic Cell Transplantation for Mantle Cell Lymphoma Using Post-Transplantation Cyclophosphamide Graft-Versus-Host Disease Prophylaxis

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Severe Cytokine Release Syndrome Is a Fatal Complication after PBSC, but Not after BM Haploidentical Transplantation with Post-Transplant Cyclophosphamide

Gvhd after PBSC-Haploidentical Stem Cell Transplantation (Haplo-SCT) with Post Transplantation-Cyclophosphamide (PT-Cy)

The Minnesota Refined Acute GVHD Score Predicts Response to Initial Therapy, Survival and Non-Relapse Mortality after Haploidentical Transplantation with Post-Transplant Cyclophosphamide

CD3 Lymphocyte Graft Content and Not Hematopoietic Stem Cell Source Is Associated to Higher Chronic GVHD after Haploidentical Transplantation with Post-Transplant Cyclophosphamide

Reduced Relapse and Improved Survival in Chemosensitive Hodgkin Lymphoma Patients Undergoing Haploidentical Related Donor Compared to HLA-Identical Donor Transplantation

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

Pharmacologic Inhibition of JAK1/JAK2 Signaling Protects from Acute GvHD While Preserving Gvt in Mice

In Vivo Jak1/Jak2 Inhibition Protects From Acute GvHD While Maintaining Robust Anti-Tumor Activity

Phase 2 clinical trial of rapamycin-resistant donor CD4 + Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation

Inhibition of Jak1/Jak2 Is More Effective Than Inhibition of Jak3 in Protecting Mice From Acute Graft-Versus-Host Disease (aGvHD) by Significantly Decreasing Alloreactive CD4+ T-Cells.

G-CSF Stem Cell Mobilization Is Protective Against Acute Graft-Versus-Host Disease (aGvHD) by Increasing Myeloid-Derived Suppressor Cell (MDSC) Frequencies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only